CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC

Initial results from a phase 1 dose escalation trial of E-602 shows efficacy in solid tumours

VT3989 is safe and well tolerated in patients with advanced malignant mesothelioma and NF2m cancers

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours

Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma

Cancer Care in Older Adults and Special Population

Why tumour markers are not recommended as screening tests

ALLO-316 demonstrates encouraging anti-tumour activity for patients with advanced or metastatic ccRCC

Applying the syndemic framework to cancer research for effective cancer control in LMICs

Addition of Salmonella-IL2 to FOLFIRINOX for metastatic stage 4 pancreatic cancer nearly doubles median survival

MatchMiner: An open-source AI precision medicine trial matching platform

Test identifies tumour-infiltrating cell densities as prognostic biomarkers across a pan-cancer cohort